Annual report
366A.TEDINET S100YKON
Period2025-04-01 → 2026-03-31
Filed2026-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks17 of 17 passed
Key figures · 107
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥14.8bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Operating income | ¥1.2bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Ordinary income | ¥1.2bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.2bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥822m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥822m | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Total assets | ¥9.7bn | at 2026-03-31 | Cons. | Assets |
| Total liabilities | ¥3.9bn | at 2026-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥5.8bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.5bn | at 2025-03-31 | Cons. | Net assets |
| Cash and deposits | ¥5.3bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥5.3bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.1bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥112m | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.5bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥68.13 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥67.41 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥467.52 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 59.9% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 14.1% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| Employees | 263 | at 2026-03-31 | Cons. | Number of employees |
| Revenue | ¥14.6bn | 2025-04-01 → 2026-03-31 | Standalone | Net sales |
| Revenue | ¥14.1bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥13.3bn | 2023-04-01 → 2024-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥10.7bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥9.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥1.2bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.2bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥955m | 2023-04-01 → 2024-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥812m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥657m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥1.2bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥805m | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥776m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥680m | 2023-04-01 → 2024-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥560m | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥443m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥7.6bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥5.2bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥4.6bn | at 2024-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.9bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥3.2bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.8bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.7bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥5.8bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥3.5bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.9bn | at 2024-03-31d | Standalone | Net assets |
| Net assets / equity | ¥2.4bn | at 2023-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥1.9bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥5.0bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.8bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥2.8bn | at 2025-03-31 | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.6bn | at 2024-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.6bn | at 2023-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.2bn | at 2022-03-31d | Standalone | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥1.7bn | 2024-04-01 → 2025-03-31 | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥555m | 2023-04-01 → 2024-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥953m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥408m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥269m | 2024-04-01 → 2025-03-31 | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥426m | 2023-04-01 → 2024-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥405m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥155m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥213m | 2024-04-01 → 2025-03-31 | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥179m | 2023-04-01 → 2024-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥148m | 2022-04-01 → 2023-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥119m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥66.7 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.23 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥62.44 | 2023-04-01 → 2024-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥51.41 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥40.65 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥65.99 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥34.4 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42.75 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥37.47 | 2023-04-01 → 2024-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30.86 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥24.4 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥466.14 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥316.77 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥264.27 | at 2024-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥217.25 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥178.04 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 76.3% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.6% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.2% | at 2024-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.5% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 17.4% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 24.5% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 25.9% | 2023-04-01 → 2024-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 26.0% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 25.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 12,463,400 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,448,200 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,448,200 | at 2024-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,448,200 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 5,448,200 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 128 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 122 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 108 | at 2024-03-31d | Standalone | Number of employees |
| Employees | 103 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 90 | at 2022-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 17
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥40m |
| Health Management Cloud Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥101m |
| Health Management Cloud Businessreportable segment | employees | at 2026-03-31 | 157 pure |
| Health Management Cloud Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.5bn |
| Health Management Cloud Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.5bn |
| Health Management Cloud Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥767m |
| Medical Checkup Solution Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥130m |
| Medical Checkup Solution Businessreportable segment | employees | at 2026-03-31 | 54 pure |
| Medical Checkup Solution Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥13.0bn |
| Medical Checkup Solution Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥13.0bn |
| Medical Checkup Solution Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥379m |
| Medical Institution Support Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥11m |
| Medical Institution Support Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥236m |
| Medical Institution Support Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥236m |
| Medical Institution Support Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥40m |
| Health Management Cloud Businessreportable segment | employees | at 2026-03-31 | 22 pure |
| Medical Checkup Solution Businessreportable segment | employees | at 2026-03-31 | 54 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,037
| Item | Context | Value | Unit |
|---|---|---|---|
| Decrease increase in notes and accounts receivable trade ope cf | CurrentYearDuration | -19875000 | JPY |
| Decrease increase in inventories ope cf | CurrentYearDuration | -9785000 | JPY |
| Increase decrease in notes and accounts payable trade ope cf | CurrentYearDuration | -10225000 | JPY |
| Increase decrease in provision for directors bonuses ope cf | CurrentYearDuration | -4200000 | JPY |
| Increase decrease in provision for directors retirement benefits ope cf | CurrentYearDuration | 6000000 | JPY |
| Increase decrease in net defined benefit liability ope cf | CurrentYearDuration | -2100000 | JPY |
| Other net ope cf | CurrentYearDuration | 14834000 | JPY |
| Subtotal ope cf | CurrentYearDuration | 1458997000 | JPY |
| Interest and dividends income received ope cf inv cf | CurrentYearDuration | 38000 | JPY |
| Interest expenses paid ope cf fin cf | CurrentYearDuration | -2922000 | JPY |
| Income taxes paid ope cf | CurrentYearDuration | -356115000 | JPY |
| Net cash provided by used in operating activities | CurrentYearDuration | 1099998000 | JPY |
| Purchase of property plant and equipment inv cf | CurrentYearDuration | -18966000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | CurrentYearDuration | 176848000 | JPY |
| Purchase of intangible assets inv cf | CurrentYearDuration | -214364000 | JPY |
| Payments for transfer of business2 inv cf | CurrentYearDuration | -70000000 | JPY |
| Payments for lease and guarantee deposits inv cf | CurrentYearDuration | -56606000 | JPY |
| Proceeds from collection of lease and guarantee deposits inv cf | CurrentYearDuration | 1108000 | JPY |
| Proceeds from purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYearDuration | 70625000 | JPY |
| Purchase of investments in subsidiaries inv cf | CurrentYearDuration | -500000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -111854000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -45233000 | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYearDuration | 1757016000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | CurrentYearDuration | 17735000 | JPY |
| Payments of listing expenses fin cf | CurrentYearDuration | -10847000 | JPY |
| Cash dividends paid fin cf | CurrentYearDuration | -232910000 | JPY |
| Other net fin cf | CurrentYearDuration | -213000 | JPY |
| Net cash provided by used in financing activities | CurrentYearDuration | 1485546000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYearDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYearDuration | 2473690000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2786458000 | JPY |
| Cash and cash equivalents | CurrentYearInstant | 5260149000 | JPY |
| Number of consolidated subsidiaries | CurrentYearInstant | 1 | |
| Accounts receivable trade | CurrentYearInstant | 1107392000 | JPY |
| Accumulated depreciation ppe by group | CurrentYearInstant | -155997000 | JPY |
| Payrolls sga | CurrentYearDuration | 850408000 | JPY |
| System related expenses sga | CurrentYearDuration | 205922000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration | 31352000 | JPY |
| Provision for directors bonuses sga | CurrentYearDuration | 19736000 | JPY |
| Provision for directors retirement benefits sga | CurrentYearDuration | 6000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | -1967000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E37743-000MedicalCheckupSolutionBusinessReportableSegmentMember | 13018494000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E37743-000HealthManagementCloudBusinessReportableSegmentMember | 1523763000 | JPY |
| Revenues from external customers | CurrentYearDuration_jpcrp030000-asr_E37743-000MedicalInstitutionSupportBusinessReportableSegmentMember | 236100000 | JPY |
| Revenues from external customers | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYearDuration | 14778359000 | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E37743-000MedicalCheckupSolutionBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E37743-000HealthManagementCloudBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_jpcrp030000-asr_E37743-000MedicalInstitutionSupportBusinessReportableSegmentMember | － | JPY |
| Transactions with other segments | CurrentYearDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 17 of 17 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |